Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96NY9

UPID:
MUS81_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q96NY9; Q9H7D9

BACKGROUND:
The Crossover junction endonuclease MUS81, in collaboration with EME1 and EME2, forms an endonuclease complex with a preference for branched DNA structures. This complex is essential for the processing of 3'-flap structures, replication forks, and nicked Holliday junctions, playing a critical role in mitosis and ensuring the integrity of DNA replication processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Crossover junction endonuclease MUS81 offers a promising pathway to identifying new therapeutic approaches. Given its central role in DNA repair mechanisms, targeting MUS81 could lead to innovative treatments that prevent or mitigate genomic instability in various diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.